1,200 articles
Max S. Wicha
Max S. Wicha is an American oncologist and cancer biologist at the University of Michigan whose lab was part of the team that first identified breast cancer stem cells.
Mel Greaves
Mel Greaves, born 1941, is a British leukemia researcher at the Institute of Cancer Research in London who proposed that common infections trigger childhood leukemia in susceptible children.
Melissa M. Hudson
Melissa M. Hudson is a pediatric oncologist at St. Jude Children's Research Hospital who directs its Cancer Survivorship Division and studies long-term outcomes of childhood cancer survivors.
Melvyn F. Greaves
Melvyn F. Greaves, born 1941, is a British cancer biologist at London's Institute of Cancer Research known for classifying leukemias and showing childhood ALL starts before birth.
Meredith M. Regan
Meredith M. Regan is a biostatistician and Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School who leads the International Breast Cancer Study Group's statistical center.
Mette Kalager
Mette Kalager is a Norwegian physician and researcher known for work on cancer screening and overdiagnosis, whose 2010 study found mammography explained only a third of Norway's breast-cancer mortality decline.
Michael A. Caligiuri
Michael A. Caligiuri is an American medical oncologist known for research on interleukin-15 and natural killer cells, and a professor at City of Hope since 2023.
Michael A. Postow
Michael A. Postow is an American medical oncologist, Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, known for leading the first randomized trial of nivolumab plus ipilimumab.
Michael B. Atkins
Michael B. Atkins is an American medical oncologist treating melanoma and kidney cancer, deputy director of Georgetown Lombardi Comprehensive Cancer Center and a leader in cancer immunotherapy.
Michael B. Kastan
Michael B. Kastan is an American cancer biologist who defined the DNA damage response pathway and its p53 and ATM signaling, and led the Duke Cancer Institute.
Michael C. Heinrich
Michael C. Heinrich is an American medical oncologist and professor at the OHSU Knight Cancer Institute, known for identifying PDGFRA mutations in gastrointestinal stromal tumor and leading trials of tyrosine kinase inhibitors.
Michael F. Leitzmann
Michael F. Leitzmann is a German cancer epidemiologist who researched physical activity, body size, and diet in relation to cancer at the National Cancer Institute and the University of Regensburg.
Michael Gnant
Michael Gnant is an Austrian breast-cancer surgeon and clinical researcher, professor of surgery at the Medical University of Vienna and president of the Austrian Breast and Colorectal Cancer Study Group.
Michael Goggins
Michael G. Goggins is an Irish-trained physician-scientist at Johns Hopkins, where he directs the Pancreatic Cancer Early Detection Laboratory and leads the CAPS pancreatic cancer screening study.
Michael J. Eck
Michael J. Eck is an American structural biologist and cancer researcher at Dana-Farber Cancer Institute and Harvard Medical School, known for kinase structures and EGFR lung-cancer drugs.
Michael J. Keating
Michael J. Keating is an Australian-born hematologist-oncologist who spent nearly five decades at MD Anderson Cancer Center, developing the FCR regimen that transformed chronic lymphocytic leukemia treatment.
Michael J. Seckl
Michael J. Seckl is a British medical oncologist, Professor of Molecular Oncology at Imperial College London, who directs the national Gestational Trophoblastic Disease Service and developed the TE/TP regimen.
Michael J. Thun
Michael J. Thun is an American cancer epidemiologist who spent 1989 to 2012 at the American Cancer Society, known for studies on aspirin's role in cancer prevention.
Michael M. Gottesman
Michael M. Gottesman is an American physician-scientist at the National Cancer Institute whose laboratory showed that the P-glycoprotein pump drives multidrug resistance in cancer cells.
Michael P. Link
Michael P. Link is an American pediatric oncologist at Stanford University whose 1986 osteosarcoma and lymphoma trials transformed childhood cancer treatment; he was ASCO's first pediatric oncologist president.
Michael Pfreundschuh
Michael Pfreundschuh (1949–2018) was a German hematologist and oncologist, professor at Saarland University in Homburg, who developed the SEREX method for identifying human tumor antigens.
Michael Platten
Michael Platten is a German neurologist and neuroimmunologist who leads brain tumor immunotherapy research at Heidelberg University, University Medicine Mannheim, and the German Cancer Research Center.
Michaël Pollak
Michaël Pollak, also published as Michael N. Pollak, is a medical oncologist and cancer researcher at McGill University in Montreal, known for work on insulin, IGF signaling, and metformin in cancer.
Michael Untch
Michael Untch, born 1957 in Transylvania, is a German gynecologic oncologist who led the breast cancer center at Helios Klinikum Berlin-Buch and shaped treatment for HER2-positive breast cancer.
Michael V. Seiden
Michael V. Seiden is an American oncologist known for ovarian cancer research and as president and CEO of Fox Chase Cancer Center from 2007 to 2013.
Michael Wang (hematologist-oncologist)
Michael (Luhua) Wang is a Chinese-American hematologist-oncologist at MD Anderson Cancer Center who directs its Mantle Cell Lymphoma Program of Excellence and has published over 150 papers.
Michel Aguet
Michel Aguet, born 1947, is a Swiss physician-scientist and professor emeritus at EPFL who cloned the human interferon-γ receptor in 1988 and directed ISREC from 1996 to 2009.
Michel Ducreux
Michel Ducreux is a French medical oncologist and gastroenterologist who heads digestive oncology at Gustave Roussy in Villejuif and is known for authoring the ESMO pancreatic cancer guidelines.
Michel P. Coleman
Michel P. Coleman is a British cancer epidemiologist, Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine since 1995.
Michelle M. Le Beau
Michelle M. Le Beau is an American cancer geneticist who directed the University of Chicago Comprehensive Cancer Center for 17 years and later led CPRIT in Texas.